Evidence map›Paper›PMID 31326265›Full record

ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2020

Resection and chemotherapy is the optimal treatment approach for patients with clinically node positive intrahepatic cholangiocarcinoma.

Sean P Martin, Justin Drake, Michael M Wach, Samantha M Ruff, Laurence P Diggs, Jim Y Wan, Meghan L Good, Dana A Dominguez, Reed I Ayabe, Evan S Glazer and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Sean P MartinSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3942, Bethesda, MD, 20892, USA.
Justin DrakeSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3942, Bethesda, MD, 20892, USA; Division of Surgical Oncology, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA.
Michael M WachSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3942, Bethesda, MD, 20892, USA.
Samantha M RuffSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3942, Bethesda, MD, 20892, USA.
Laurence P DiggsSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3942, Bethesda, MD, 20892, USA.
Jim Y WanDivision of Surgical Oncology, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA.
Meghan L GoodSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3942, Bethesda, MD, 20892, USA.
Dana A DominguezSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3942, Bethesda, MD, 20892, USA.
Reed I AyabeSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3942, Bethesda, MD, 20892, USA.
Evan S GlazerDivision of Surgical Oncology, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA.
Paxton V DicksonDivision of Surgical Oncology, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA.
Jeremy L DavisDivision of Surgical Oncology, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA.
Jeremiah L DeneveDivision of Surgical Oncology, Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA. Electronic address: jdeneve@uthsc.edu.
Jonathan M HernandezSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4-3942, Bethesda, MD, 20892, USA. Electronic address: jonathan.hernandez@nih.gov.
National Institutes of Health · USUniversity of Tennessee Health Science Center · US

Funding

TGIB Surgical Consultative ServicesZIDBC011541 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHRUMP, DAVID · 2014 to 2018
$12.8M
Evaluating outcomes for patients with primary-metastatic gastrointestinal cancerZIABC011861 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HERNANDEZ, JONATHAN · 2019 to 2025
$166k
Intramural NIH HHS ZIA BC011861Intramural NIH HHS ZID BC011541
6 · The paper itself

Abstract

backgroundClinically lymph node positive (cLNP) intrahepatic cholangiocarcinoma (ICC) carries a poor prognosis, without clear management guidelines for the practicing clinician. We sought to evaluate current practice patterns for cLNP ICC, including associations with survival.

methodsThe National Cancer Database was queried for patients with cLNP ICC, without extrahepatic metastases.

resultsWe identified 1023 patients with cLNP ICC, 77%% (n = 784) of whom received chemotherapy alone. Resection was undertaken in 23% (n = 239) of patients and was most commonly utilized in combination with chemotherapy (n = 150). Median survival for all patients was 13.6 months. Patients undergoing resection in combination with chemotherapy were associated with an improved survival (22.5 months) as compared to those patients receiving chemotherapy alone (11.9 months) or resection alone (12.4 months) (p < 0.01). Finally, we compared the survival of patients with cLNP ICC with that of patients with pathologically proved lymph node positive (pLNP) ICC, all of whom were treated with resection with chemotherapy, and found no difference in survival (22.5 months-19.3 months, p = 0.99, respectively).

conclusionsWhile the decision to pursue resection for ICC is multifactorial and patient specific, the presence of clinically positive LNs should not represent a contraindication.

Indexed as

AgedBile Duct NeoplasmsCholangiocarcinomaCombined Modality TherapyDatabases, FactualFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm StagingPractice Patterns, Physicians'Retrospective StudiesSurvival RateUnited States

Identifiers

PMID31326265
PMCPMC8456743
OpenAlexW2956968292

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.